Abstract
MicroRNAs (miRNAs) are small non-coding RNAs that can negatively regulate gene expression at the post-transcriptional level through the RNA-induced silencing complex (RISC)-mediated inhibition. Because of the imperfect and short seed-binding region of the target sequences, miRNAs hold capacity for multi-targeting and are able to regulate a wide range of cellular functions and signaling. Numerous researches have revealed that dysregulated miRNAs are closely associated with cancer progression. Moreover, genome-wide screening shows that the expression profile of miRNAs can serve as biomarkers for early diagnosis, stratifying patient outcome, and predicting treatment efficiency for cancer patients. Hence, seeking and dissecting the detailed mechanisms of cancer-associated miRNA may provide a new avenue for cancer targeting therapy. This review discussed the current proposed mechanisms of miR-135b involvement in cancer progression and tissue differentiation, both of which are considered as functional equivalents. The regulatory network of miR-135b are also addressed to further clarify the potential oncogenic role of miR-135b.
Highlights
Several lung cancer-associated miRNAs have recently been identified
An up-regulated miR-135b is highly associated with poor overall survival in non-small cell lung cancer (NSCLC)
The oncogenic mechanism is via the suppression of LZTS1 and multiple components of the Hippo pathway
Summary
Several lung cancer-associated miRNAs have recently been identified. Among them, miR-135b antisense stands out for its therapeutic potential or its oncogenic role [1,2,3]. An up-regulated miR-135b is highly associated with poor overall survival in non-small cell lung cancer (NSCLC). The various oncogenic functions of miR-135b may be attributed to its multi-targeting ability, which involves different mechanisms during tumor progression. The oncogenic roles of miR-135b on cancer stemness and drug-resistance are yet to be clarified.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
